MedKoo Cat#: 112002 | Name: tcY-NH2 TFA salt
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

tcY-NH2 is a synthetic peptide antagonist of proteinase-activated receptor 4 (PAR4) that corresponds to amino acids 1-6 of the amino terminal tethered ligand sequence of mouse PAR4. It inhibits platelet aggregation induced by the PAR4 agonist AYPGKF-NH2 in washed isolated rat platelets (IC50 = 95-190 µM), as well as induces relaxation of isolated rat aortic rings precontracted with phenylephrine and contraction of isolated rat gastric longitudinal muscle strips (EC50s = 64 and 1 µM, respectively). tcY-NH2 (400 µM) inhibits thrombin-induced migration of primary hepatocellular carcinoma (HCC) cells. It reduces myocardial infarct size as a percentage of the area at risk ex vivo in a isolated rat heart model of ischemia-reperfusion injury.

Chemical Structure

tcY-NH2 TFA salt
tcY-NH2 TFA salt
CAS#NONE

Theoretical Analysis

MedKoo Cat#: 112002

Name: tcY-NH2 TFA salt

CAS#: NONE

Chemical Formula: C42H50F3N7O9

Exact Mass:

Molecular Weight: 853.90

Elemental Analysis: C, 59.08; H, 5.90; F, 6.67; N, 11.48; O, 16.86

Price and Availability

Size Price Availability Quantity
1mg USD 500.00 2 Weeks
5mg USD 1,150.00 2 Weeks
10mg USD 1,900.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
tc-YPGKF-NH2; trans-cinnamoyl-YPGKF-amide; trans-cinnamoyl-YPGKF-NH2; tcY-NH2; tcY-NH2 TFA salt; tcY-NH2-TFA salt; tcY-NH2 trifluoroacetate salt
IUPAC/Chemical Name
(S)-N-(2-(((S)-6-amino-1-(((S)-1-amino-1-oxo-3-phenylpropan-2-yl)amino)-1-oxohexan-2-yl)amino)-2-oxoethyl)-1-(cinnamoyl-L-tyrosyl)pyrrolidine-2-carboxamide 2,2,2-trifluoroacetate
InChi Key
WQJKBSZTPQERHW-USBDLMLUSA-N
InChi Code
InChI=1S/C40H49N7O7.C2HF3O2/c41-22-8-7-14-31(38(52)46-32(37(42)51)24-28-12-5-2-6-13-28)44-36(50)26-43-39(53)34-15-9-23-47(34)40(54)33(25-29-16-19-30(48)20-17-29)45-35(49)21-18-27-10-3-1-4-11-27;3-2(4,5)1(6)7/h1-6,10-13,16-21,31-34,48H,7-9,14-15,22-26,41H2,(H2,42,51)(H,43,53)(H,44,50)(H,45,49)(H,46,52);(H,6,7)/b21-18+;/t31-,32-,33-,34-;/m0./s1
SMILES Code
NC([C@@H](NC([C@@H](NC(CNC([C@H]1N(CCC1)C([C@H](CC2=CC=C(C=C2)O)NC(/C=C/C3=CC=CC=C3)=O)=O)=O)=O)CCCCN)=O)CC4=CC=CC=C4)=O.OC(C(F)(F)F)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Solvent mg/mL mM
Solubility
DMF 12.0 14.05
DMSO 10.0 11.71
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 853.90 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Fang H, Yuan Z, Zhu Y, Tang H, Pang C, Li J, Shi J, Guo W, Zhang S. Blocking protease-activated receptor 4 alleviates liver injury induced by brain death. Biochem Biophys Res Commun. 2022 Mar 5;595:47-53. doi: 10.1016/j.bbrc.2022.01.074. Epub 2022 Jan 21. PMID: 35093640. 2: Gomides LF, Lima OC, Matos NA, Freitas KM, Francischi JN, Tavares JC, Klein A. Blockade of proteinase-activated receptor 4 inhibits neutrophil recruitment in experimental inflammation in mice. Inflamm Res. 2014 Nov;63(11):935-41. doi: 10.1007/s00011-014-0767-8. Epub 2014 Aug 14. PMID: 25118784. 3: Iqbal J, Naeem K, Siddiqui R, Khan NA. In vitro inhibition of protease- activated receptors 1, 2 and 4 demonstrates that these receptors are not involved in an Acanthamoeba castellanii keratitis isolate-mediated disruption of the human brain microvascular endothelial cells. Exp Parasitol. 2014 Nov;145 Suppl:S78-83. doi: 10.1016/j.exppara.2014.03.023. Epub 2014 Apr 2. PMID: 24703976. 4: Mende K, Reifart J, Rosentreter D, Manukyan D, Mayr D, Krombach F, Rentsch M, Khandoga A. Targeting platelet migration in the postischemic liver by blocking protease-activated receptor 4. Transplantation. 2014 Jan 27;97(2):154-60. doi: 10.1097/01.TP.0000437430.89485.a0. PMID: 24434483. 5: Chang Y, Huang SK, Lu WJ, Chung CL, Chen WL, Lu SH, Lin KH, Sheu JR. Brazilin isolated from Caesalpinia sappan L. acts as a novel collagen receptor agonist in human platelets. J Biomed Sci. 2013 Jan 25;20(1):4. doi: 10.1186/1423-0127-20-4. PMID: 23350663; PMCID: PMC3564834. 6: Jardin I, Ben Amor N, Bartegi A, Pariente JA, Salido GM, Rosado JA. Differential involvement of thrombin receptors in Ca2+ release from two different intracellular stores in human platelets. Biochem J. 2007 Jan 1;401(1):167-74. doi: 10.1042/BJ20060888. PMID: 16939417; PMCID: PMC1698687. 7: Hollenberg MD, Saifeddine M. Proteinase-activated receptor 4 (PAR4): activation and inhibition of rat platelet aggregation by PAR4-derived peptides. Can J Physiol Pharmacol. 2001 May;79(5):439-42. PMID: 11405248.